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Brief summary: This study involving more than 500 children <5 years of age from India 
showed that the quantity of vaccine virus shedding after administration of oral poliovirus vaccine 
is positively correlated with the magnitude of serum neutralizing antibodies developed 
subsequently.  
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Abstract 
Replication of oral poliovirus vaccine (OPV) in the intestine (vaccine ‘take’) is associated with 
seroconversion and protection against poliomyelitis. We used quantitative PCR to measure 
vaccine shedding in 300 seronegative infants aged 6-11 months and in 218 children aged 1-4 
years 7 days after administration of monovalent or bivalent OPV. We found the quantity of 
shedding correlated with the magnitude of the serum neutralizing antibody response measured at 
21 or 28 days respectively. This suggests the immune response to OPV is on a continuum, rather 
than an all-or-nothing phenomenon, that depends on efficient vaccine virus replication. 
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Background 
Oral poliovirus vaccine (OPV) contains live-attenuated (Sabin) polioviruses that can replicate at 
mucosal sites in the gastrointestinal tract and induce mucosal and systemic antibody. Virus 
replication can be detected shortly after vaccination and persists for a median time of about 2-3 
weeks in stool [1].The probability of replication (vaccine ‘take’) following vaccine 
administration depends on a number of factors, including the potency of the vaccine, maternal 
antibodies, pre-existing immunity and infection with other enteric viruses [2;3]. Vaccine take and 
seroconversion is substantially lower when administered to infants in low compared with high 
income countries [4]. 
Intestinal antibodies to poliovirus can be detected in stool beginning in the second week after 
vaccination, and coincide with a decline in the amount of poliovirus shed [5] . The development 
of neutralizing antibodies in serum is usually measured 4 weeks after vaccination and is 
associated with detection of vaccine poliovirus shedding, such that the majority of children who 
seroconvert have poliovirus in their stool after vaccination [6]. Thus, poor immunogenicity and 
efficacy of OPV in low-income countries is typically characterized as a problem of vaccine take 
[6]. In this view, OPV is an ‘all-or-nothing’ vaccine that either‘takes’ and induces protective 
serum neutralizing antibodies or not. Detection of these antibodies at a dilution of 1 in 8 or more 
is a mechanistic correlate of protection against poliomyelitis [7]. Virus specific CD8+ T-cells can 
also be detected after vaccination with OPV, but the contribution of cellular immunity to 
protection against poliomyelitis is unknown [8]. 
We recently conducted two clinical trials of oral and inactivated poliovirus vaccines in Indian 
infants aged 6-11 months and in children 1-4 years old [9;10]. We used quantitative real-time 
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PCR to accurately quantify poliovirus shedding in stool after vaccination with OPV, and 
measured serum neutralizing antibody responses at a range of dilutions. Here we present an 
analysis of these data to determine the association between the quantity of vaccine poliovirus 
shedding and the magnitude of the immune response.  
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Methods 
Study design and sample collection 
A total of 300 infants aged 6-11 months, and 218 children aged 1-4 years were included in the 
study. The 300 infants were part of a randomized placebo-controlled trial 
(CTRI/2014/05/004588) evaluating the effect of prophylactic azithromycin treatment on the 
immunogenicity of serotype 3 monovalent OPV (mOPV3) in Indian infants who lacked 
antibodies against this serotype [9]. The children were vaccinated with mOPV3 containing 
atleast 10
5.8
 CCID50 (median cell culture infectious dose) of serotype-3 poliovirus 
(GlaxoSmithKline Biologicals, Belgium). Serum samples were collected pre-vaccination and 21 
days post-vaccination, and stool samples 7 days post-vaccination. All infants completing the 
study (intention-to-treat) were included in this study. 
The 218 children aged 1-4 years (12-59 months) were part of an open label, randomized 
controlled trial (CTRI/2012/09/003005) examining the effect of one dose of IPV or no vaccine 
on poliovirus shedding after a subsequent dose of serotype 1 and 3 bivalent OPV (bOPV) in 
Indian children who had received OPV at least 6 months previously [10]. Here we include 
children from the no vaccine arm who received bOPV 28 days after enrolment, and who 
provided a blood sample at the time of vaccination, a stool sample 7 days later and a second 
blood sample after 28 days.  
Both the studies were conducted in Vellore, India, and approved by the Institutional Review 
Board of Christian Medical College, Vellore and the Drugs Controller General of India. 
Informed consent was obtained from the parents/legal guardians of all study subjects. 
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Neutralization test for anti-poliovirus antibodies 
For the infants aged 6-11 months, pre-vaccination serum samples were tested at 1:4 and 1:8 
dilutions by a modified micro-neutralization assay according to World Health Organization 
(WHO) guidelines and only children seronegative to type-3 poliovirus were enrolled in the study 
(antibody titer <1:8) [11;12]. Post-vaccination samples were tested in 2-fold serial dilutions from 
1:4 to 1:512 to determine serotype 3 neutralizing antibody response. For the children aged 1-4 
years, pre- and post- vaccination serum samples were tested for serotype 1 and 3 neutralizing 
antibodies in 2-fold serial dilutions from 1:8 to 1:1024. Seroconversion was defined as either i) 
seronegative (antibody titer <8) to seropositive (antibody titer ≥8), or ii) a 4 fold rise in antibody 
titer for children who were seropositive before vaccination. 
Quantitative real-time PCR for PV1 and PV3 
Quantitative real-time polymerase chain reaction (PCR) assays were performed to determine 
Sabin poliovirus 1 and 3 shedding in stool samples as previously described [9;10]. Standard 
curves using poliovirus plasmids ranging from 3x10
7
 to 3 copies/µl were used to determine the 
detection limit, which was 3 copies per reaction with a cycle threshold (Ct) cutoff value of <40 
for both assays (Sabin 1 and 3).  
 
Statistical Analysis 
Correlation between poliovirus shedding and serum neutralizing antibody titres was assessed as 
continuous (log-scale) and categorical (yes/no) variables using Pearson’s correlation coefficient 
and Fisher’s exact test respectively. Differences in the mean quantity of poliovirus shed by 
seroconversion or shedding status were assessed using the non-parametric Wilcoxon rank sum 
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test. The geometric mean titres (GMTs) of antibodies among the children at the time of 
vaccination were calculated by assigning a value of 1:6 and 1:1448 for the censored values 
below and above the limits of the dilution series respectively. A P-value <0.05 was considered 
statistically significant. All tests were two-tailed. 
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Results 
Of the 300 PV3 seronegative infants aged 6-11 months who were given a dose of mOPV3, 160 
(53.3%) had serotype 3 Sabin poliovirus (PV3) detected in stool on day 7 after vaccination. 
Among these infants, 85% seroconverted to serotype 3 poliovirus at 21 days post-vaccination 
(Table 1). Among those who did not have PV3 detected in stool, only 10% seroconverted 
(Fisher’s exact test P<0.001). The quantity of Sabin PV3 shed was significantly higher in the 
group that seroconverted compared to those who did not seroconvert (Wilcoxon Rank Sum 
(WRS) test, P-value<0.001). In addition, the quantity of shedding was correlated with the titer of 
serum neutralizing antibodies achieved 21 days post-vaccination (Pearson’s correlation 
coefficient 0.508, P-value <0.001; Figure 1A). 
Of the 218 children aged 1-4 years, who were given a dose of bOPV, 42 (19.3%) and 56 (25.7%) 
shed serotype 1 or 3 Sabin poliovirus 7 days after vaccination respectively. Of the children who 
shed serotype 1 Sabin poliovirus (PV1), 29 (69.0%) had seroconverted 28 days after vaccination, 
whilst only 15 (8.5%) of non-shedders seroconverted (Fisher’s exact test P-value <0.001; Table 
1). Similarly, 46 (82.1%) children who shed Sabin PV3 seroconverted, and just 21 (13%) of non-
shedders (Fisher’s exact test P-value <0.001). Among children shedding vaccine polioviruses, 
the quantities of both PV1 and PV3 shed in children who seroconverted was significantly higher 
than in children who did not seroconvert (WRS P-values 0.013 and 0.011 respectively; Table 1). 
In addition, the quantity of poliovirus shedding correlated with the titer of serum neutralizing 
antibodies achieved 28 days post-vaccination, although this was not significant (Pearson’s 
correlation coefficients 0.298 and 0.212 for serotypes 1 and 3 respectively, P-values = 0.0552 
and 0.118; Figure 1B). 
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Infants enrolled to the study lacked serum neutralizing antibodies to serotype 3 poliovirus as per 
the study protocol, which involved screening for these antibodies before enrolment. Among the 
children aged 1-4 years, 215 (98.6%) and 205 (94.0%) had detectable serum neutralizing 
antibodies against serotypes 1 and 3 at the time of vaccination, with a geometric mean titer 
among these children of 221 (standard error 24.6) and 111 (15.8) respectively. Children who 
shed vaccine poliovirus had significantly lower baseline antibody titers than those who did not 
shed (142 vs. 236 and 72.2 vs. 115 for serotypes 1 and 3 respectively, WRS P-values 0.017 and 
0.033).   
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Discussion 
Whether a child sheds vaccine poliovirus in stool after immunization with OPV (vaccine ‘take’) 
is known to predict seroconversion [6]. In addition, the appearance of poliovirus-specific IgA in 
stool and blood from about 2 weeks after administration of OPV typically correlates with a 
decline in the amount of poliovirus shed [5;13]. Previous studies have speculated that the amount 
of virus replication could determine the magnitude of the antibody response, but have been 
limited to observations from very few individuals or to comparisons between children 
immunized with inactivated or oral poliovirus vaccines [5;14]. Using quantitative PCR, we were 
able to address this question in over 500 individuals and found that the quantity of poliovirus 
shed 7 days after vaccination is positively correlated with the magnitude of the subsequent serum 
neutralizing antibody response. A stool virus titer of about 4 log copy number was associated 
with a higher antibody response in the infants aged 6-11 months (Figure 1A), whereas for 
children aged 12-59 months, a substantial antibody response was observed even with a stool 
virus titre of about 3 log copy number (Figure 1B). This suggests that the amount of poliovirus 
replication in the intestine in the first weeks following immunization determines the amount of 
neutralizing antibody produced during the initial response.  
We also found an inverse relationship between preexisting neutralizing antibody titer in children 
and the probability of shedding homotypic virus in stool after vaccination. This has previously 
been shown in several studies of OPV immunized individuals mainly from high-income 
countries [3]. This same relationship is not observed among individuals immunized with 
inactivated poliovirus vaccine, which induces limited mucosal protection despite high titers of 
serum neutralizing antibodies [15].  
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Our study had some limitations. We only quantified poliovirus in stool on day 7 after vaccination 
and we therefore may have missed early shedding and were unable to estimate the duration or 
dynamics of shedding over time. Also, we did not directly measure fecal antibody or mucosal 
tissue immune response. This could perhaps be the focus of a smaller study where pediatric 
endoscopy would allow collection of intestinal tissue.  
In conclusion, we found that both seronegative infants and seropositive children aged 1-4 years 
immunized with OPV made poliovirus-specific antibody in proportion to the amount of vaccine 
poliovirus detected in stool. This indicates the response to OPV is on a continuum rather than an 
all-or-nothing (‘take’ based) phenomenon. Overcoming the poor immunogenicity of OPV in 
LMICs may therefore require strategies to promote vaccine poliovirus replication. These could 
include the development of new genetically stable and replication efficient vaccine strains or 
complementary therapies such as probiotics.  
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Table 1: Correlation between Sabin poliovirus shedding (on day 7 after vaccination), and 
subsequent seroconversion  
 
Age, 
Serotype 
 
 
Shedding day 7 Not shedding day 7 P-values 
  Seroconversion Seroconversion  
  Yes No Yes No  
6-11 
months, 
PV3 
Number 136 24 14 126 <0.001 
log10 virus copy number per 0.2 g 
stool, mean (SE) 
4.70 
(0.11) 
2.27 
(0.33) 
 
NA NA <0.001 
12-59 
months, 
PV1 
Number  29 13 15 161 <0.001 
log10 virus copy number per 0.2 g 
stool, mean (SE) 
3.41 
(0.28) 
2.11 
(0.39) 
 
NA NA 0.013 
12-59 
months, 
PV3 
Number  46 10 21 141 <0.001 
log10 virus copy number per 0.2 g 
stool, mean (SE) 
3.01 
(0.19) 
1.66 
(0.45) 
NA NA 0.011 
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Figure legends 
Figure 1: Quantity of poliovirus shed compared with serum neutralizing antibody titer achieved 
after vaccination with A) serotype 3 monovalent OPV in infants and B) serotypes 1 and 3 
bivalent OPV in children aged 1-4 years. Poliovirus shedding was measured using quantitative 
PCR and is shown on a log base 10 scale. Antibody titers are shown as the reciprocal of the 
dilution at which neutralization was detected in half the wells calculated using the Spearman-
Karber method. 
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